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Supplementary Information accompanies this paper on the Leukemia website (http://www.nature.com/leu) Complete mutational spectrum of the autophagy interactome: a novel class of tumor suppressor genes in myeloid neoplasms Leukemia (2017) 31, 505-510; doi:10.1038/leu. 2016.295 Autophagy is an evolutionarily conserved mechanism of bulk protein degradation. Aberrant autophagic activity contributes to the pathogenesis of many diseases including cancer. 1, 2 Although allelic loss-of key autophagy genes such as ATG6/BECN1 has been specifically associated with malignancies, the prevalence of mutations in the autophagy network as a whole has never been comprehensively studied in a diverse spectrum of patients with myeloid neoplasms. 3 We conducted a cross-sectional analysis of 180 autophagy genes and their interactions by analyzing the results of whole-exome sequencing (WES) derived from a cohort of 223 cases with myeloid neoplasms ((N = 223; myelodysplastic syndromes (MDS) = 120, acute myeloid leukemia (AML) = 46, MDS/ myeloproliferative neoplasms (MPN) = 45, MPN = 5 and others (paroxysmal nocturnal hemoglobinuria (PNH), aplastic anemia/ PNH = 7)). We also reviewed the TCGA data of patients with primary AML (N = 202). In total, we identified missense mutations and copy number alterations in the following genes of the autophagy network (ATG2A, ATG4C, ATG14, ATG16L1, BCL2, CDKN2AIPNL, COG8, DNM1L, DNM2, GYS1, HIF1A, KIF1B, LAMP2, MLST8, MTOR, NOD2, PIK3C2G, PIK3C2A/B, PIK3CB, PPP2R2A/B, PPP2R3A, PRKACB, PRKAA1/2, PRKAG1/G2, PTPN2, RICTOR, RPTOR, SEC22B, SMURF1, SQSTM1, STAT3, SUPT20H, TAB2, TNFSF10/13B, ULK4, USP10, VPS11/33B, VTI1A, WDFY3/4, WAC) in 40 patients (MDS = 14, AML = 15, MPN, MDS/MPN = 9 and others = 2). Bioinformatic analyses detected genetic alterations in at least one relevant gene in 31/223 (14%) of patients with available WES and in 9/202 (4.4%) of patients from the TCGA cohort (Table 1) . Supplementary  Table S1 summarizes the clinical characteristics of the patients carrying mutations in autophagy-related genes (pt#1-31 (our cohort) and 32-40 (TCGA cohort)). The analysis of matched CD3 + lymphocytes confirmed the somatic nature of each alteration. Mutations were: non-synonymous (45), stopgain (5), frameshift insertions/deletions (3/1), non-frameshift deletion (1) and splice site (3); 32/40 patients had a sole mutation, 4 patients carried 2 mutations each (ULK4, WDFY3), (KIF1B, SEC22B), (VIT1A, TAB2), (DNM2, WAC). Two patients harbored mutations in three genes each (pt#10 (RPTOR, SQSTM1, GYS1) and pt#13 (TNFSF10, LAMP2, PTPN2)). One patient (pt#15) carried two mutations in the NOD2 gene (stopgain (13.5%) and a missense (8.2%)). One patient (pt#1) had 43 mutations. We also identified recurrently mutated genes: PRKACB (pt#1 (AML stage), 14 and 24), ULK4 (pt#1 (MDS stage), #2), NOD2 (pt#1 (AML stage), #15), PTPN2 (pt#13, 17), PRKAG1 (pt#25, 26), VPS11 (pt#29, 30) and WAC (pt#32, 40). The same mutation (p.T192P; c.A574C) in the v-SNARE coiled-coil homology domain of SEC22B gene was also detected in pts#6 and #27. We designed a mutational diagram by clustering all the genes based on their function in the autophagy pathway ( Figure 1a ) and classified the mutations in the following autophagy interactome components: apoptotic effectors/inducers (13/55; 24%), protein kinases and dependent kinases (10/55; 18%), vesicle transport (9/55; 16%), early-stage autophagy (8/55; 15%) and phosphatidylinositol-3 phosphatase family (6/55; 11%; Supplementary Figure S1a ). In the cohort of mutant patients, mutations were observed in more than 10% of all myeloid disease types with the majority of mutant patients being high-risk MDS (12/40; 30%) and AML patients (15/40; 37.5%) (Supplementary Figure S1b) . A schematic diagram depicts two genes (PRKACB, ULK4) that were found mutated in three and two patients, respectively (Figure 1b ). Of note, the association of mutations in the autophagy pathway with higher grade rather than lower grade MDS disease is emphasized by the analysis of consecutive samples. Indeed, we performed WES of patients #1 and 13 in paired specimens obtained at the stage of MDS and after progression to AML. We found a high mutation level in early-stage autophagy (ULK4; 12.5%) genes and in the mTOR pathway (MTOR (10%) and RICTOR (16.7%)) at the stage of MDS in patient #1. Mutations in apoptotic effectors and inducers (BCL2; 14.2% (MDS stage) vs NOD2; 63% (AML stage)) and in the protein kinase phosphatase pathway (PPP2R2A; 7.1% (MDS stage) vs PPP2R3A; 10% (AML stage)) were detected at both the MDS and AML stages. This patient had multiple adverse features including a complex karyotype, TP53 and PRPF8 mutations, a rapid increase in bone marrow (BM) blasts with disease progression (3% vs 35% in 3 months) and no response to hypomethylating therapy. In patient #13, we observed the emergence of mutations in autophagy-related genes such as TNFSF10 (7.6%), LAMP2 (7.7%) and PTPN2 (8%) only at the AML stage and not at the MDS stage. These characteristics suggest that alterations in autophagy-related genes may be a cooperative event associated with disease progression and that cells with autophagic defects may be more susceptible to clonal evolution. Analysis of the cytogenetic profiles of the mutant patients showed that four genes mapped to commonly deleted regions, for example, 5q (CDKN2AIPNL, SQSTM1) or 7q (SMURF1, PRKAG2) and coincided with haploinsufficient expression, whereas three genes had hemizygous configuration (SMURF1, PPP2R3A, PIK3C2G) ( Supplementary Table S2 ). Analysis of the variant types showed that loss-of-function mutations were observed in ULK4 (stopgain; p.L1220X), NOD2 (stopgain; p.E1008X), VTI1A (stopgain; p.E53X), PTPN2 (stopgain; p.R26X), PRKAA2 (stopgain; p.R227X), VPS11 (frameshift insertion; p.S64fs*), DNM2 (frameshift insertion; T471fs*), WAC (frameshift insertion; p.E87fs) and USP10 (frameshift deletion; p.P386fs*) genes. We also dissected the clonal hierarchy of autophagy gene mutations. Clonal hierarchy showed that autophagy mutations were predominantly secondary events, were ancestral events in seven patients (ATG2A, SEC22B, STAT3, PRKACB, DNML1, PTPN2, PRKAG1) and co-dominant in two patients (NOD2, MLST8). When autophagy gene mutations were secondary, the most represented ancestral mutations were in splicing factors (N = 9; SRSF2, PRPF8, U2AF1) and DNA methylation genes (N = 4; TET2, DNMT3A). The characterization of ancestral vs secondary events suggested to us that autophagy gene mutations are cooperative rather than initiating events in clonal evolution. We also observed that autophagy gene mutations are secondary mutations in several cases when ancestral mutations occurred in splicing factor genes. A recent article reported that autophagy genes may be implicated in the epigenetic mechanism of patients with MDS carrying U2AF1 mutations and may contribute to disease phenotypes. U2AF1 S34 mutation has been described to possibly promote leukemogenesis by aberrant splicing of the autophagy gene ATG7. 4 This observation led us to investigate whether epigenetic defects in autophagy genes are also commonly detected in MDS and, if present, whether they correlate with specific biological and clinical MDS phenotypes. We analyzed RNA sequencing of patients with MDS and found that the expression levels of several autophagy genes were increased in SF3B1 MUT MDS compared with SF3B1 WT MDS cells: early-stage autophagy genes (ATG2A/B, FC = 2; ATG4A, FC = 2; ATG9A, FC = 5; ATG4C, P = 0.05; ATG18 (FC = 4.8; P = 0.02), autophagy-initiating kinases (ULK1, FC =2; ULK3, FC = 3.9; P = 0.05) and late stage autophagy genes (CTSL1, FC = 20; CTSD, FC = 5.8; P = 0.05; CTSB, FC = 2.1; CTSE, FC = 5.9; CTSD, FC = 2; P = 0.01). Of note, two genes (ATG2A and ATG4C) carried somatic mutations and increased expression levels. One of them, ATG2A was also an ancestral event when mutated. We originally reported a list of genes found differentially expressed in Sf3b1 +/ − murine BM cells compared with Sf3b1 +/+ murine BM cells 5 ( Supplementary Table S1 ) by RNA sequencing analysis. Interestingly enough, we merged the list of genes found mutated in our cohort of patients with the list of genes found modulated in Sf3b1 +/− mice and found that 17 genes were up-regulated more than twofold change in our mouse model of MDS (ATG16L1, PIK3CB, GYS1, SEC22B, KIF1B, STAT3, VT1A, TNFSF10, PTPN2, DNML1, DNM2, HIF1A, MLST8, CDKN2AIPNL, WAC, BCL2, USP10). These observations suggested that the autophagy pathway can potentially be targeted in MDS cells for therapeutic benefit. Autophagy gene mutations were most prevalent in high-risk MDS (12/40; 30%) and almost equally prevalent in sAML and pAML patients (6/9). A total of 21/37 (57%) had abnormal karyotype with 4 patients having complex karyotype including − 17 and − 7. Among the cases with abnormal karyotype, 4 cases had del (5q). Overall, 21 patients had a fatal outcome. Comparative analysis of Sanger sequencing, TruSeqtargeted DNA sequencing, WES and TCGA data was used to assess the global mutational spectrum of the patients harboring mutations in the autophagy network. We found that the most commonly mutated gene was TET2 (11/40; 27.5%), followed by RUNX1 and STAG2 (8/40; 20%), SRSF2 (7/40; 7.5%) and DNMT3A and ASXL1 (6/40; 15%). Hemizygosity due to somatic deletions for genes associated with poor prognosis was also noted (TP53: 2 patients; PRPF8, CUX1, DDX41: 1 patient each) ( Figure 1c ). Comparative analysis (Sanger, TruSeq, WES, TCGA) found that patients with autophagy-related genes are more susceptible to acquire mutations in signal transduction pathways (26 mutations), DNA methylation (24 mutations) and RNA-splicing (20 mutations) (Figure 1c; Supplementary Figure S2 ). Twenty-five mutations had a cut-off more than 20% variant allele frequency (Supplementary Figure S3 ). Targeted-gene panel sequencing was applied for 22 genes and confirmed the presence of high-variant allele frequency mutations like NOD2 (63%), PIK3C2B (44%), PRKACB (36%) and STAT3 (38%). The majority of mutant patients had a dismal prognosis, suggesting that these patients had cumulative unfavorable mutations like RUNX1, ASXL1, DNMT3A and that these negative prognostic mutations 6 represented driver mutations in these patients. Seven patients receiving hypomethylating agents had no response to therapy ( Supplementary Table S1 ). Comparison of mutant and wild type (WT) patients showed that mutant patients had lower survival trending toward significance compared with WT (14 months vs 20 months; N MUT vs N WT = 20 vs 90; log-rank = 0.09). Among disease subtypes, autophagy network mutations were associated with significantly inferior survival in patients with MDS (N MUT = 13, mean survival: 17 months; N WT = 61, mean survival: 35 months, log-rank: 0.0187) and MDS/MPN overlap syndromes (N MUT = 4, mean survival: 12 months; N WT = 31, mean survival: 30 months, log-rank: 0.0374).
Given the recent discovery of familial AML and MDS cases carrying pathogenic germline variants, 7, 8 we also evaluated whether the same autophagy genes we found to be somatically mutated may also be prone to germline alterations. An in house analysis of a database of 263 973 variants obtained from WES was conducted by testing different predictive tools assessing deleterious variants and by calling a variant as deleterious if present as deleterious in all predictive scores (Supplementary Methods). We found four variants in three genes among four patients with possible deleterious exonic non-synonymous variants that were predicted to be significantly damaging by all the tested scores: PIK3C2G (rs377020826, c.T3083C, total allele frequency: 0.0001; rs201569993, c.C2938T, total allele frequency: 0.0007), NOD2 (rs104895423, c.T662G, total allele frequency: 0.0006) and HIF1A (c.A1666G; total allele frequency: undetermined) ( Supplementary  Table S3 ). In total, PIK3C2G carried one somatic and two germline variants, NOD2 had two somatic and one germline variants, and HIF1A harbored one somatic and one germline variant. A complete table summarizes the somatic and germline status of the variants we identified in the autophagy pathway ( Supplementary  Table S4 ).
As mentioned previously, many types of malignant cells have been reported to exhibit defective or dysregulated autophagy including mutations in BECN1 (17q21), which is monoallelically deleted in 40-75% of patients with breast, ovarian and prostate cancer. 9 In other tumors, autophagy genes such as SH3GLB1 have been associated with regions of loss-of heterozygosity. 10 In our study, we identified mutations in proximal co-factors of BECN1 such as PI3KCIII, vacuolar sorting proteins (Vps34, Vps11) and ATG14. We performed an analysis of the related protein sequences (http://www.uniprot.org/) of the mutated regions and found that several mutations occurred in essential domains/regions involved in protein-protein interactions, particularly those required for autophagosome formation (ATG14, BECN1, PI3KC3, SEC22B, VPS34/11) ( Table 1) . Several mutations were found in functional domains of the proteins (pt#32 (DNM2; pleckstrin homology domain), pt#38 (PRKAA2; protein kinase domain)). Other mutations were detected in regions of interactions between genes highly relevant in the autophagy pathway such as WDFY3 mutation (p.G3362V; pt#2) maps in a region spanning the interaction with SQSTM1 (amino-acid 2586-3526), ATG5 (amino-acid 2981-3526) and the region containing the LC3-interacting region (LIR) motif, which allows the targeting of autophagy receptors to LC3 (or other ATG8 family proteins) as a crucial step in the autophagy cascade. SQSTM1 was also found mutated in our cohort (p.D347Y; pt#10) and the mutated region was proximal to the LIR motif (amino-acid 336-341). We also detected a mutation in a Beclin-1associated autophagy key regulator (ATG14; pt#33), which has been shown to directly interact with Beclin-1 and increases phosphatidylinositol-3-phosphate kinase class III (PI3KC3) activity to initiate autophagosome membrane nucleation by targeting SNARE-associated proteins. 11 We also reviewed extensively the literature to identify possible variants occurring also in other diseases ( Supplementary Table S5 ).
Our collective findings define for the first time an important and perhaps so far underappreciated role for genetic aberrations in the autophagy network in the pathogenesis of myeloid neoplasms. Our data demonstrate that autophagy-related gene mutations are more prevalent in MDS and AML, co-occur with unfavorable mutations (RUNX1, ASXL1, DNMT3A), and are associated with inferior survival. These findings support further investigation of genetic loss-of autophagy regulation as a novel cooperative mechanism leading to leukemogenesis that can potentially be therapeutically targeted with synthetic lethal approaches. Results from high-throughput next-generation sequencing collected from a larger population of genetically annotated patients with myeloid neoplasms and comprehensive clinical information from different institutional centers will help define the exact frequency of single gene mutations and the precise correlation with the clinical phenotypes.
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